NCT06587503View on ClinicalTrials.gov

Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

May 31, 2025

Conditions

Ebola Virus DiseaseCOVID-19

Interventions

BIOLOGICAL

BioNTech - Pfizer COVID-19 vaccine

Vaccine for protection from COVID-19

BIOLOGICAL

1mL saline solution

Placebo

BIOLOGICAL

rVSV∆G-ZEBOV-GP

Vaccine for protection from Zaire Ebola virus

All Listed Sponsors

collaborator

Project San Francisco

UNKNOWN

collaborator

Rwanda Biomedical Centre

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Birmingham

OTHER

NCT06587503 - Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses | Biotech Hunter | Biotech Hunter